Company Performance Metrics
The Cytonet Group is an international biotechnology company with sites in Weinheim, Germany and Durham, NC, USA. Cytonet has 60 employees and develops and produces cell-therapeutic products which could offer alternatives for existant therapies, e.g. organ transplantation. In order to provide a cellular medicinal product for the treatment of urea
cycle defects, cells from donated but non-transplantable livers are gently isolated and processed in a complex procedure developed by Cytonet.
Managing directors are Dr. Wolfgang Rüdinger and Dipl.-Kfm. Michael J. Deissner. Cytonet was founded by a demerger from the Roche Group in April 2000. The Dietmar Hopp family owns the majority of shares.
The SELICA study on liver cell therapy as a treatment for inborn errors of liver metabolism in neonates and infants is currently ongoing in Germany and the USA
